Generation of anti-trenbolone monoclonal antibody and establishment of an indirect competitive enzyme-linked immunosorbent assay for detection of trenbolone in animal tissues, feed and urine

Trenbolone (TRE) is a steroid used by veterinarians on livestock to increase appetite and body weight. The use of TRE has been restricted because of its harmful side effect for consumers. To effectively control TRE residue in food and food product, a rapid and convenient immunoassay was developed by preparing an anti-TRE monoclonal antibody. The immunogen and coating antigen were prepared by coupling TRE hapten with carrier proteins via 1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride (EDC) method. The optimized method gave an average IC₅₀ value of 0.323 ng mL⁻¹ towards TRE and an average detection limit (LOD) of 0.06 ng mL⁻¹, which is much lower than the maximum residue levels (2.0 ng g⁻¹) accepted by the Joint FAO/WHO Expert Committee on Food Additives (JECFA). The specificity of the antibody was evaluated by measuring cross-reactivity of six structurally related compounds, including 19-nortestosterone (9.7%), testosterone (0.13%), methyltestosterone (<0.01%), methandrostenolone (<0.01%), (+)-dehydroisoandrosterone (<0.001%) and β-estradiol (<0.001%). The recovery rates of the test in detection of TRE-fortified animal tissue, urine and animal feed samples were in the range of 81.3-89.4%, while the intra- and inter-assay coefficients of variation were less than 12.0%.     

Dinuclear copper(II) perchlorate complexes with 6-(benzylamino)purine derivatives: Synthesis,X-ray structure,magnetism and antiradical activity

The reactions of Cu(ClO₄)₂·6H₂O with 6-(benzylamino)purine derivatives in a stoichiometric 1:2 metal-to-ligand ratio led to the formation of penta-coordinated dinuclear complexes of the formula [Cu₂(μ-L^1–8)₄(ClO₄)₂](ClO₄)₂·nsolv, where L¹ = 6-(2-fluorobenzylamino)purine (complex 1), L² = 6-(3-fluorobenzylamino)purine (2), L³ = 6-(4-fluorobenzylamino)purine (3), L⁴ = 6-(2-chlorobenzylamino)purine (4), L⁵ = 6-(3-chlorobenzylamino)purine (5), L⁶ = 6-(4-chlorobenzylamino)purine (6), L⁷ = 6-(3-methoxybenzylamino)purine (7) and L⁸ = 6-(4-methoxybenzylamino)purine (8); n = 0–4 and solv = H₂O, EtOH or MeOH. All the complexes have been fully characterized by elemental analysis, FTIR, UV–Vis and EPR spectroscopy, and by magnetic and conductivity measurements. Variable temperature (80–300 K) magnetic susceptibility data of 1–8 showed the presence of a strong antiferromagnetic exchange interaction between two Cu(II) (S = 1/2) atoms with J ranging from −150.0(1) to −160.3(2) cm⁻¹. The compound 6·4EtOH·H₂O was structurally characterized by single crystal X-ray analysis. The Cu?Cu separation has been found to be 2.9092(8) Å. The antiradical activity of the prepared compounds was tested by in vitro SOD-mimic assay with IC₅₀ in the range 8.67–41.45 μM. The results of an in vivo antidiabetic activity assay were inconclusive and the glycaemia in pre-treated animals did not differ significantly from the positive control.     

Production of monoclonal antibodies against hop-derived (Humulus lupulus L.) prenylflavonoids and the development of immunoassays

Monoclonal antibodies against the hop-derived prenylated chalcone xanthohumol (X) and the prenylated flavonoids isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) were developed. Carboxylic acid haptens of X, IX and 8-PN were synthesized by linking a spacer to their C4′-OH group followed by subsequent coupling to bovine serum albumin (BSA) to form conjugates that were employed as immunogens in BALB/c mice to raise antibodies. The monoclonal antibodies that were secreted from the established hybridoma cell lines proved, in cross-reactivity studies, to possess highly specific binding capacities in an optimized competitive indirect ELISA. The immunoassays make use of immunogen-coated microtiterplates and a peroxidase-labeled anti-mouse IgG₁ secondary antibody with ABTS as a chromogenic substrate. For X the IC₅₀ value derived from the standard curve was 62.91 ng mL⁻¹, and for both IX and 8-PN 37.15 ng mL⁻¹. The assay was validated for the quantitative analysis of X, IX and 8-PN in urine and serum. A simple sample pretreatment procedure using a diethyl ether extraction was optimized and the recoveries and matrix effects were assessed. The validity of the established assay was tested and mean inter- and intra-assay variations in urine were 2.32% and 1.91%, respectively for X, 6.24% and 2.39%, respectively for IX and 7.18% and 0.74%, respectively for 8-PN. In serum, the mean inter- and intra-assay variations were 8.90% and 1.37%, respectively for X, 6.13% and 1.57%, respectively for IX and 6.13% and 2.43%, respectively for 8-PN. Furthermore, the method demonstrated excellent accuracy and significant correlation with measurements by an established and validated HPLC-MS method.